Major histocompatibility complex class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunity
|
|
- Aleesha Nash
- 1 years ago
- Views:
Transcription
1 Proc. Natl. Acad. Sci. USA Vol. 94, pp , June 1997 Immunology Major histocompatibility complex class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunity TODD D. ARMSTRONG*, VIRGINIA K. CLEMENTS*, BRIAN K. MARTIN, JENNY P.-Y. TING, AND SUZANNE OSTRAND-ROSENBERG* *Department of Biological Sciences, University of Maryland Baltimore County, Baltimore, MD 21250; and Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC Communicated by Ray D. Owen, California Institute of Technology, Pasadena, CA, April 22, 1997 (received for review February 14, 1997) ABSTRACT We have developed an immunotherapy in which tumor cells transfected with syngeneic major histocompatibility complex (MHC) class II genes are cell-based vaccines for the treatment of established tumor and metastatic disease. If this strategy is to be used clinically, convenient methods for generating class II tumor cells are necessary. Interferon- treatment or transduction of the class II transactivator (CIITA) gene induces class II expression but also up-regulates the class II-associated accessory molecules, invariant chain (Ii) and DM. To determine if interferon- treatment and CIITA transduction are potential immunotherapies, we assessed the tumorigenicity of sarcoma cells expressing combinations of class II, Ii, and DM. Since we hypothesized that class II-transfected tumor cells not coexpressing Ii and DM present endogenously encoded tumor peptides, we have assessed the transfectants for antigen presentation activity to MHC class II-restricted antigen-specific CD4 T cells. Tumor challenge studies demonstrate that tumor cells expressing class II without coexpression of Ii or Ii plus DM are highly immunogenic and preferentially present endogenous antigens, while tumors coexpressing class II with Ii or Ii plus DM are not effective immunogens. Because tumor rejection correlates with expression of class II without coexpression of Ii and DM, the most efficacious vaccines will express MHC class II without coexpression of Ii and DM and will preferentially present endogenous antigen. Numerous strategies for enhancing the immune response to autologous tumors have recently been developed. Many of the approaches directly target the activation of tumor-specific CD8 effector T lymphocytes, since these cells are efficient mediators of tumor-specific immunity (1). In contrast, we (2, 3) and others (4 6) have reasoned that improved generation of tumor-specific CD4 T helper cells enables tumor-specific CD8 T cells to function more efficiently and, therefore, have focused on activating CD4 T cells. We have used gene transfection to express syngeneic major histocompatibility complex (MHC) class II genes in tumor cells so that the tumor cells can directly present tumor peptides to CD4 T helper lymphocytes and bypass the need for host antigen-presenting cells (APC) and soluble tumor antigen. Immunization of autologous mice with class II-transfected tumor cells protects against subsequent challenges of wild-type (class II ) primary tumor in a sarcoma model (2), decreases metastatic disease in two melanoma models (7), and mediates regression of a wild-type, long-term established, solid tumor in a sarcoma model (8). T cell depletion experiments established that class II-transfected tumor cells stimulate tumor-specific CD4 T The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C solely to indicate this fact by The National Academy of Sciences $ cells because they are more immunogenic than wild-type class II tumor cells (2, 8). Immunization with class II-transfected tumor cells, therefore, induces a potent tumor-specific immunity that could be exploited for immunotherapy. To develop the CD4 T cell activation strategy and methods for predicting its potential clinical application, we are exploring additional approaches to enhance MHC class II expression. The two most practical of these approaches, interferon (IFN- ) treatment (9) and class II transactivator (CIITA) gene transduction (10), not only increase autologous MHC class II expression but also up-regulate class II-associated accessory molecules, such as invariant (Ii) chain and DM (11 13). If IFN- treatment and or CIITA gene expression are to be considered as immunotherapeutic strategies for treating tumor-bearing patients, the effects of class II-associated accessory molecule expression on class II-transfected tumor cell immunogenicity should be determined. We have, therefore, generated and determined the tumorigenicity of various sarcoma transfectants expressing different combinations of syngeneic MHC class II, Ii, and DM. Since we originally hypothesized that class II-transfected tumor cells that do not coexpress class II accessory molecules will present endogenously synthesized tumor peptides (2, 3), we have also assessed the ability of the various transfectants and transductants to present MHC class II-restricted antigen to antigen-specific CD4 T cells. Our results demonstrate that tumor cells expressing syngeneic MHC class II without coexpression of Ii and DM are the only transfectants transductants that induce tumorspecific immunity and efficiently present class II-restricted, endogenously synthesized antigens. Tumor cell coexpression of Ii and DM along with class II, therefore, abrogates the protective effects of class II expression, probably by preventing tumor cells from presenting endogenously synthesized tumor antigen(s). If cell-based vaccines using class II-transfected tumor cells are to be used as immunotherapeutic agents to generate tumor-specific CD4 T cells, then the most effective vaccines will express MHC class II molecules and will not coexpress Ii and DM molecules. EXPERIMENTAL PROCEDURES Mice and Tumor Challenges. All mice were purchased from The Jackson Laboratory and or bred in the University of Maryland Baltimore County animal facility. For tumor challenges, mice were inoculated intraperitoneally (i.p.) with 10 6 tumor cells. This dose was chosen on the basis of previous in Abbreviations: MHC, major histocompatibility complex; APC, antigen-presenting cells; IFN-, interferon ; CIITA, class II transactivator; HEL, hen eggwhite lysozyme; mhel, membrane-expressed HEL; ER, endoplasmic reticulum; erhel, ER-expressed HEL; Ii, invariant chain; IL-2, interleukin 2. To whom reprint requests should be addressed. umbc.edu. 6886
2 Immunology: Armstrong et al. Proc. Natl. Acad. Sci. USA 94 (1997) 6887 vivo tumor cell titrations (2, 14). After tumor challenge, mice were checked for tumor incidence 2 3 times per week, and sacrificed when moribund. Tumor-challenged mice were observed for up to 3 months and were considered tumor-free if they did not develop a palpable tumor during the observation period. Tumor incidence is the number of mice with tumor divided by the total number of mice injected. Cell Lines. SaI, SaI A k, and SaI A k Ii transfectants were generated as described (2, 15). All tumor cells, transfectants, and transductants were maintained in Iscove s modified Dulbecco s medium (IMDM) supplemented with 5% Fetalclone I (HyClone), 1% penicillin, and 1% streptomycin. Additionally, SaI A k, SaI A k Ii, and SaI CIITA transfectants were maintained in 400 g ml G418, and lysozyme transfectants, in 400 g ml hygromycin. Cells transfected with both psv2neo and psv2hph plasmids were maintained in G418 and hygromycin. SaI A k Ii cells were periodically enriched for class II expression by magnetic bead separation (Dynal). Plasmids and Retrovirus Preparation. Plasmid pklk contains a viral promoter driving the hen eggwhite lysozyme (HEL) gene linked to the MHC class I transmembrane region of H-2K b (16). This construct was used to generate SaI sarcoma cells expressing a membrane-bound HEL (mhel). Plasmid phyk contains a viral promoter driving the HEL gene fused to a KDEL endoplasmic reticulum (ER) retention signal (erhel) (17). These plasmids were the generous gifts of C. Goodnow and H. Pelham, respectively. Plasmid psv2hph contains the hygromycin phosphotransferase gene (14). The extrachromosomal expression vector BCMGhph (18) was kindly provided by D. Pardoll. Plasmid BCMGhph-erHEL was generated by subcloning a blunt-ended HindIII BamHI fragment containing the HEL gene from the phyk plasmid into the unique XhoI site of the BCMGhph vector. For the CIITA construct, the EcoRI EcoRI fragment of the pcdna3.flag.ciita construct (58) was cloned into the EcoRI site of the LXSNb retroviral plasmid, and production of retrovirus was as described (19). Transfectants and Transductants. Transfections were performed as previously described (15) using l of Lipofectin (GIBCO) and g of psv2hph plus g of pklk per 10 6 cells in 3 ml for mhel or 10 g of BCMGhpherHEL per 10 6 cells in 3 ml for erhel transfectants. Transfectants were selected using 400 g ml hygromycin (Calbiochem). mhel transfectants were cloned by limiting dilution. For retroviral infection, 10 5 SaI cells in mid-logarithmic growth phase were incubated for 2 hr with 250 l of viral supernatant containing 8 mg ml Polybrene. After incubation, the viral supernatant was replaced with fresh growth medium. Two days later the cells were passaged 1:20 and placed in selection (400 g ml G418). The polyclonal population was then analyzed for class II expression and cloned by limiting dilution. Antigen-Presentation Assays. Antigen-presentation assays were performed in 96-well flat-bottomed plates in a total volume of 300 l per well of IMDM supplemented with 10% heat-inactivated Fetalclone I, 1% penicillin, and 1% streptomycin. HEL-(46 61)-specific, I-A k -restricted 3A9 hybridoma cells (20) were irradiated with 2,200 rads (1 rad 0.01 Gy) and mixed ( per well) with SaI-derived APC (23,000 rads) or irradiated (2,400 rads) TA3 control B lymphoma cells (21). In initial experiments, ratios of 1:1, 2:1, and 5:1 3A9:APC were used. A ratio of 1:1 3A9:APC was used in subsequent experiments because it consistently gave the highest stimulation values. Cells were incubated at 37 C for 24 hr, and 50- l samples of the supernatants were either frozen or assayed immediately for interleukin 2 (IL-2). IL-2 was measured by ELISA using an Endogen (Cambridge, MA) IL-2 kit and following the instructions of the supplier. For exogenous antigen presentation, intact or trypsin-digested HEL (22) was added to each well to a final concentration of 1 mg ml. All wells were prepared in triplicate, and the average and standard deviation for each experimental condition were determined. Standard deviations usually did not exceed 5 10%. Antibodies. Hybridoma cell lines secreting the lysozymespecific mabs HyHEL 7 and HyHEL 10 (23) were kindly supplied by S. Smith-Gill and were affinity purified on protein G as described (2). The MHC class I (11 4.1: H-2K k -specific) and invariant chain (In-1) mabs have been described (2, 15) is an MHC class II I-A k -specific mab (24). The polyclonal rabbit antiserum K553 against mouse DM (H-2M) was kindly supplied by L. Karlsson (25). Immunofluorescence. Live cells were stained by indirect immunofluorescence for cell surface markers (MHC class II, class I, mhel) as described (2), using the , , or a cocktail of HyHEL 7 plus HyHEL 10 mabs. Cells stained for internal markers (Ii, erhel, DM) were fixed in 1% or 2% paraformaldehyde, permeabilized with 0.2% saponin, and then stained as for live cells (2) except 0.2% saponin was included in the wash medium and in all diluted reagents. erhel transfectants were stained with a cocktail of HyHEL 7 plus 10 mabs followed by a goat anti-mouse IgG-fluorescein isothiocyanate (FITC) conjugate (Cappel). Ii transfectants were stained with the In-1 mab followed by an F(ab ) 2 goat anti-rat IgG-FITC conjugate (Cappel). CIITA transductants were stained with the polyclonal rabbit anti-dm (no. K553) antiserum followed by an F(ab ) 2 goat anti-rabbit IgG-FITC (Cappel). Cells were analyzed on a Coulter XL flow cytometer. RESULTS Sarcoma Tumor Cells Transfected with Syngeneic MHC Class II Genes Are Rejected by Autologous or Semisyngeneic Mice, While Sarcoma Cells Expressing Class II plus Ii Chain, With or Without DM, Are Highly Malignant. Tumor expression of autologous MHC class II molecules can be increased by several methods, including transfection or transduction of class II genes (2), incubation of tumor cells with IFN- (9), or expression of the CIITA gene (10, 12, 26 29). Although the latter two approaches induce MHC class II expression, they also induce expression of the class II-associated accessory molecules Ii and DM. To determine if coexpression of Ii and DM with class II affects the therapeutic value of class IItransfected tumor cells, we have generated transfectants transductants expressing class II genes and various combinations of Ii and DM and have tested their immunogenicity. Fig. 1 shows flow cytometry profiles of wild-type SaI sarcoma cells, SaI cells expressing syngeneic MHC class II A k and A k genes (SaI A k tumor cells), SaI A k cells expressing Ii (SaI A k Ii tumor cells), and SaI cells transduced with the CIITA gene (SaI CIITA tumor cells). Tumor cells were stained by indirect immunofluorescence for syngeneic MHC class II molecules (I-A k ), Ii, or DM. Cell-surface MHC class II expression was assessed on live cells, while internal Ii and DM expression was assessed in fixed cells. As shown in Fig. 1A, wild-type SaI cells do not express I-A k, Ii, or DM (panels a, o, or u, respectively), while SaI A k cells express I-A k but not Ii or DM (panels d, r, and v, respectively). As shown in Fig. 1B, three clones of SaI A k Ii cells (clones 6, 7, and 9) express I-A k (panels a, c, and e) and intracellular Ii (panels p, r, and t) but not DM (panels w, x, and y). SaI CIITA cells express I-A k, Ii, and DM (Fig. 1C, panels d, t, and y), while vector-alonetransduced SaI cells (SaI LXSN) do not express class II, Ii, or DM (Fig. 1C panels a, q, and x.) MHC class I levels on these cells are comparable to class I levels on SaI sarcoma cells (data not shown, but see refs. 2 and 15). In previous studies, immunotherapeutic potential of SaI transfectants correlated with their tumorigenicity (2, 8, 15, 30). To test the immunogenicity of the transfectants and transductants, mice were challenged i.p. with tumor cells and monitored for ascites tumor growth and survival. Both autologous
3 6888 Immunology: Armstrong et al. Proc. Natl. Acad. Sci. USA 94 (1997) (A J) and semisyngeneic [(C57BL 6 A J)F 1 ] mice were used because previous experiments have established that SaI tumor growth is the same in both strains (ref. 31 and T.D.A., unpublished results). As shown in Table 1, wild-type class II SaI, SaI A k Ii, and SaI CIITA tumor cells are highly tumorigenic. SaI A k Ii lines have been tested for tumorigenicity in A J mice, and they were found to form tumors in % of tested animals (15). SaI A k tumor cells, however, are uniformly rejected. These results agree with earlier findings that class II-transfected tumor cells are highly immunogenic in autologous hosts, while tumor cells coexpressing Ii are lethal. Optimal immunogenicity and tumor rejection, therefore, occur when sarcoma cells express syngeneic MHC class II molecules and do not coexpress class II-associated accessory molecules. SaI Tumor Cells Transfected with the HEL Gene Express Lysozyme in the Appropriate Targeted Cellular Compartment. We originally hypothesized that class II-transfected tumor cells that do not coexpress Ii and or DM would present endogenously synthesized tumor peptides and be effective APC that activate CD4 T h (helper) lymphocytes (2, 3). Such tumor cells should be significantly more immunogenic than wild-type class II tumor cells. To determine if this hypothesis explains the differential tumorigenicity of the SaI, SaI A k, SaI A k Ii, and SaI CIITA tumors, we have assessed their relative ability to present MHC class II-restricted antigen to CD4 T cells. Since our hypothesis is that class II-transfected tumor cells would be more efficient presenters of any class II-restricted endogenous antigen, SaI sarcoma cells were transfected with the HEL gene, and presentation of lysozyme as an endogenous antigen has been assessed. HEL serves as a convenient model antigen in these studies for two reasons: I-A k -restricted hybridomas (20) and cloned lysozyme genes (17, 16) are available for measuring HEL presentation. Furthermore, sarcoma transfectants expressing HEL in the ER (erhel) or plasma membrane (mhel) have been generated, thereby mimicking some of the intracellular locations in which tumor antigens are localized. As shown in Fig. 1, SaI, SaI A k, SaI A k Ii, and SaI CIITA tumor cells transfected with the erhel plasmid (SaI erhel, SaI A k erhel, SaI A k Ii erhel, and SaI CIITA erhel cells, respectively), or the mhel plasmid (SaI mhel, SaI A k mhel, SaI A k Ii mhel, and SaI CIITA mhel cells, respectively) express lysozyme in the ER or at the plasma membrane (Fig. 1A, panels g n; Fig. 1B, panels h o; and Fig. FIG. 1. Expression of MHC class II, Ii, and HEL in SaI and SaI-transfected tumor cells. (A) SaI and SaI A k sarcoma cells and their transfectants were stained for MHC class II (a f), ER-retained HEL (g j), plasma membrane HEL (k n), Ii (o t), or DM (u and v). (B) Three SaI A k Ii transfected sarcoma lines (Ii-6, Ii-7, Ii-9) were stained for MHC class II (a g), ER-retained HEL (h k), plasma membrane HEL (l o), Ii (p v), or DM (w y). (C) SaI LXSN or SaI CIITA sarcoma cells and their transfectants were stained for MHC class II (a g), ER-retained HEL (h k), plasma membrane HEL (l p), Ii (q w), or DM (x and y). In all panels, broken lines represent specific antibody staining; solid lines represent secondary fluorescent conjugate staining without primary antibody. MHC class II ( mab) and plasma membrane HEL (HyHEL 7, HyHEL 10 mabs) staining was performed on live cells; internal HEL (ER-retained) and Ii chain staining was performed on fixed cells. Table 1. Sarcoma cells expressing syngeneic MHC class II molecules are rejected, while sarcoma cells coexpressing class II plus accessory molecules are lethal in autologous and semi-syngeneic mice Tumor cells Dose Tumor incidence A J (C57BL 6 A J)F 1 SaI SaI A k SaI A k Ii NT 4 5 SaI A k Ii NT 8 9 SaI A k Ii NT 8 10 SaI LXSN SaI CIITA The indicated number of sarcoma cells were inoculated i.p. into autologous A J or semisyngeneic (C57BL 6 A J)F 1 mice, and the mice were followed for tumor incidence. NT, not tested. Institutional Animal Care and Use Committee guidelines mandate that moribund animals be sacrificed to minimize pain and discomfort. On the basis of previous studies, mean survival times of these mice would have been days.
4 Immunology: Armstrong et al. Proc. Natl. Acad. Sci. USA 94 (1997) C panels h p). MHC class II (I-A k ), Ii, and DM expression in the transfectants is comparable to expression in the nonlysozyme-transfected tumors (Fig. 1). Cell lines transfected with vector alone show class II, Ii, and HEL levels comparable to untransfected parental cells (Fig. 1 C and data not shown). MHC class I antigen expression in lysozyme transfectants is comparable to expression in untransfected cells (data not shown). Transfection of these tumor cells with the HEL gene, therefore, yields tumor cells that express lysozyme in the appropriate cellular compartment, and maintain MHC class II, class I, Ii, and or DM expression comparable to their nonlysozyme-transfected relatives. Class II-Transfected Tumor Cells Present ER-Retained Endogenously Synthesized HEL Provided They Do Not Coexpress Ii. To determine if class II-transfected sarcoma cells present endogenously synthesized antigens, SaI A k erhel tumor cells were co-cultured with the I-A k -restricted lysozymespecific 3A9 hybridoma, and IL-2 secretion was measured. As shown in Table 2, SaI A k erhel cells stimulate IL-2 production, while control SaI erhel cells do not. SaI A k cells, therefore, express a functional MHC class II molecule, and present ER-retained endogenously synthesized antigen. To determine if Ii and DM coexpression affect presentation of ER-retained lysozyme, two SaI A k Ii erhel clones and SaI CIITA erhel cells were also tested as APC. As shown in Table 2, neither SaI A k Ii erhel nor SaI CIITA erhel cells cause IL-2 release. Class II tumor cells, therefore, present ER-retained antigen; however, coexpression of Ii or Ii plus DM prevents presentation. Class II-Transfected and CIITA-Transduced, but Not Ii- Transfected, Tumor Cells Present Membrane-Associated HEL. To determine if class II-transfected sarcoma cells present endogenously synthesized antigen targeted to the plasma membrane, SaI mhel, SaI A k mhel, SaI A k Ii mhel, and SaI CIITA tumor cells were tested as APC to 3A9. As shown in Table 3, SaI A k mhel cells induce IL-2 synthesis, while control SaI mhel cells do not. Two clones of SaI A k Ii mhel cells also do not stimulate IL-2 release, while SaI CIITA mhel cells do. Class II-transfected sarcoma cells, therefore, present endogenously synthesized antigen targeted to the plasma membrane if class II is expressed alone, or coexpressed with Ii and DM; however, tumor cells expressing class II and Ii without DM do not present membrane-targeted antigen. Sarcoma Tumor Cells Do Not Present Exogenous Intact Lysozyme Unless They Are Transduced with the CIITA Gene. We originally hypothesized that class II-transfected sarcoma cells are more immunogenic because they preferentially present endogenously synthesized tumor antigens. An alternative explanation for their increased immunogenicity is that they are efficient processors and presenters of exogenously synthesized antigen. To distinguish these two possibilities, SaI or SaI A k sarcoma cells were incubated with 3A9 hybridoma cells in the presence of exogenous intact HEL. TA3 cells, which Table 2. SaI A k, but not SaI A k Ii or SaI CIITA, tumor cells present peptides derived from ER-retained lysozyme APC (erheltransfected) Exp. 1 Exp. 2 Exp. 3 Exp. 4 Exp. 5 Exp. 6 SaI or SaI LXSN SaI A k SaI A k Ii SaI A k Ii SaI CIITA APC are transfectants expressing approximately equivalent levels of erhel (see flow cytometry profiles in Fig. 1). APC were cocultured with 3A9 hybridoma cells, and IL-2 release was measured by ELISA. Six independent experiments are shown. Table 3. SaI A k and SaI CIITA, but not SaI A k Ii, cells effectively present membrane-associated HEL APC (mheltransfected) Exp. 1 Exp. 2 Exp. 3 Exp. 4 Exp. 5 Exp. 6 SaI or SaI LXSN SaI A k SaI A k Ii SaI A k Ii SaI CIITA ,749 SaI CIITA , All APC are transfectants expressing approximately equal quantities of mhel (see Fig. 1 for flow cytometry quantitation). APC were incubated with HEL-specific 3A9 T cell hybridoma cells, and IL-2 release was measured by ELISA. Six independent experiments are shown. are professional APC, were included as a reference standard. As shown in Table 4, neither SaI nor SaI A k cells stimulate IL-2 release, while TA3 cells consistently stimulate high levels of IL-2 release. Class II-transfected sarcoma cells are, therefore, unable to process and or present exogenous intact antigen. Since numerous studies have demonstrated that Ii and DM expression can have profound effects on presentation of exogenous antigen by class II APC (32, 33), we assessed presentation of exogenous antigen by sarcoma cells coexpressing class II, Ii, and Ii plus DM. SaI A k Ii and SaI CIITA cells were incubated with 3A9 hybridoma cells in the presence of exogenous intact HEL, and IL-2 production was measured. As shown in Table 4, three independent SaI A k Ii clones and control SaI LXSN sarcoma cells are unable to present exogenous HEL, while SaI CIITA sarcoma cells present exogenous antigen, although the presentation is less efficient than by the professional APC, TA3. The ability to present exogenous intact antigen, is, therefore, limited to sarcoma cells that express class II, Ii, and DM. Class II-Transfected Tumor Cells Present Low Levels of Exogenously Synthesized HEL Peptide. As shown in Table 4, class II-transfected tumor cells do not present exogenously synthesized antigen unless they coexpress Ii and DM. Lack of presentation may be due to the cells inability to internalize and process antigen or to their inability to bind and present peptide. If class II-transfected tumor cells are unable to internalize and process exogenous antigen but are able to bind and present peptide, then transfectants given peptide antigen should activate antigen-specific hybridomas. To distinguish these possibilities, class II-transfected tumor cells were pulsed with trypsin-digested HEL in the presence of 3A9 hybridoma cells, and IL-2 production was measured. As shown in Table 5, SaI A k cells present lysozyme peptide better than they present intact lysozyme (compare with Table 4), but not as efficiently as the professional APC line, TA3. Since studies by other Table 4. Only CIITA-transduced sarcoma cells efficiently present exogenous intact HEL APC Exp. 1 Exp. 2 Exp. 3 SaI SaI A k SaI A k Ii SaI A k Ii SaI A k Il SaI LXSN 15 SaI CIITA TA3 3,696 1,386 3,234 APC were incubated with intact soluble HEL and 3A9 hybridoma cells, and IL-2 production was measured by ELISA. Three independent experiments are shown.
5 6890 Immunology: Armstrong et al. Proc. Natl. Acad. Sci. USA 94 (1997) Table 5. Exogenous HEL peptides are presented most efficiently by SaI cells expressing MHC class II without coexpression of Ii and DM APC Exp. 1 Exp. 2 Exp. 3 SaI or SaI LXSN SaI A k SaI A k Ii SaI A k Ii SaI CIITA TA3 1,333 1,472 2,746 APC, HEL, and 3A9 T cell hybridomas were incubated with trypsin-digested HEL. IL-2 release was measured by ELISA. Three independent experiments are shown. investigators have demonstrated that coexpression of Ii and DM significantly affects presentation of exogenous antigen (25, 34), we have also assessed SaI A k Ii and SaI CIITA as APC for exogenous lysozyme peptide. As shown in Table 5, one of the SaI A k Ii lines does not present exogenous peptide, while the second SaI A k Ii line and SaI CIITA cells minimally present exogenous peptides. Class II-transfected sarcoma cells, therefore, are inefficient presenters of exogenous peptide relative to professional APC, and coexpression of Ii or Ii plus DM reduces presentation efficiency further. DISCUSSION Immunization of tumor-bearing mice with syngeneic MHC class II-transfected autologous tumor cells yields significant regression of established primary sarcoma tumors (8). If this approach is to be used clinically, it will be necessary to develop convenient methods for generating class II tumor cells. The two most practical methods, treatment with IFN- (9) and transfection transduction of the CIITA gene (10), also upregulate the class II-associated accessory molecules, Ii and DM (11 13), but our results demonstrate that tumor cells coexpressing class II with Ii, or Ii plus DM are not effective immunogens against tumor. IFN- or CIITA gene expression is, therefore, unlikely to be useful clinically. Furthermore, if cell-based vaccines aimed at stimulating tumor-specific CD4 T h cells are to be adapted clinically, they should contain MHC class II molecules, and not coexpress Ii and DM. Some human tumors either constitutively express MHC class II or are inducible for class II expression by IFN- (e.g., melanoma and mammary carcinoma). However, tumor cell class II expression does not always correlate with disease prognosis (35, 36). Since constitutively class II tumor cells and IFN- -treated tumor cells coexpress Ii and DM, these cells are probably not any more efficient at inducing a tumor-specific CD4 T cell response than class II tumor cells. Hence, in situ class II expression by tumor cells is unlikely to be a prognostic indicator for tumor regression. Although the immunotherapeutic effect of class IItransfected sarcoma cells has been demonstrated (8, 14, 37), the mechanism of action has not been characterized. We originally hypothesized that class II Ii tumor cell transfectants present endogenously encoded tumor antigen(s) in the context of self MHC class II to CD4 T cells (3, 15, 37). This hypothesis is consistent with numerous published studies on the mechanism of class II-mediated antigen presentation, including (i) experiments showing that class II molecules present endogenously synthesized peptides (38 42), although they usually present exogenously synthesized antigens (43); (ii) demonstration that the MHC class II heterodimer binds endogenously synthesized antigen in the ER, provided Ii chain is not present (44); and (iii) sequence analysis studies demonstrating that endogenous peptides are bound to cell surface MHC class II dimers (45). Our studies are consistent with this hypothesis, since they demonstrate that class II-transfected sarcoma cells present class II-restricted endogenously encoded antigen. An alternative mechanism for the increased immunogenicity of class II-transfected tumor cells is that they endocytose exogenous antigen and re-present it. Three observations argue against this mechanism: (i) Class II-transfected tumor cells do not present exogenous intact antigen (Table 4). (ii) Class II-transfected tumor cells are inefficient presenters of exogenous peptide (Table 5). (iii) SaI CIITA tumor cells, which present exogenous intact antigen, are tumorigenic (Table 1). Therefore, presentation of exogenous antigen does not correlate with tumor cell immunogenicity, and re-presentation of exogenous antigen is unlikely to contribute to tumor rejection. Taken together, these data suggest that the most likely mechanism for enhanced immunogenicity of class II-transfected sarcoma cells is their ability to activate CD4 T cells by means of cell surface expression of MHC class II tumor peptide complexes. Several studies suggest that coexpression of Ii is required for expression of functional MHC class II molecules (46 48). Other studies, however, including those reported here (Tables 2, 3, and 5), demonstrate that class II molecules are functional in the absence of Ii (39, 40, 44). Other studies suggest that I-A k and I-E k are less dependent on Ii coexpression for functional integrity (49). In addition to the tumors reported here, we have also transfected H-2 b and H-2 d tumors (melanoma B16 and mammary carcinoma 4T1, respectively) with syngeneic MHC class II genes and shown that these tumors stimulate tumor immunity (ref. 7; B. A. Pulaski and S.O.-R., unpublished results). Other investigators have transfected I-A k or I-E k class II genes into other tumors and shown functional expression of class II molecules in the absence of Ii (4, 50). Therefore, for at least three MHC haplotypes and five different tumors, transfection of MHC class II genes results in expression of functional class II molecules. The immunotherapeutic strategy described here uses autologous tumor cells as the immunogen. Not all human malignancies will be amenable to this approach, since not all cancers can be cultured or transduced in vitro. However, phase I II clinical trials using autologous tumor cells as immunotherapeutic agents are currently underway for a variety of human tumors [neuroblastoma, breast, melanoma, prostate, glioma, papilloma ( Although the focus of our studies has been immunization with gene-modified tumor cells, we have also defined some of the molecules that facilitate T cell activation. By understanding which molecules effectively induce tumor immunity, one may be able to design more effective vaccines. Several scenarios may be possible if ex vivo autologous tumor cells are not available. Genes encoding known antigen-presentation molecules (i.e., MHC class II, B7, etc.) could be introduced in situ by viral transduction (51) or liposomes (52). Alternatively, autologous nontumor cells that are more easily manipulated in vitro (e.g., fibroblasts), transduced with the requisite antigen-presentation molecules and tumor antigen genes, could be used as vaccines. Since new tumor antigens are routinely being identified and characterized (53 55), and fibroblasts have been shown to be effective delivery vehicles (56, 57), this approach is theoretically feasible. Noncellular delivery methods, such as liposomes reconstituted ex vivo with the relevant tumor antigen peptides plus antigen-presentation molecules, could also be used. Regardless of the delivery approach, successful immunotherapy will require a full understanding of antigen-presentation molecules and tumor peptides that yield optimal T cell activation. We thank Drs. C. Goodnow, D. Gerlier, S. Smith-Gill, L. Karlsson, and S. Adams for kindly providing gene constructs, mabs, and cell lines, and Ms. Sandy Mason for her excellent care of our mice. This work was supported by National Institutes of Health Grants R01
6 Immunology: Armstrong et al. Proc. Natl. Acad. Sci. USA 94 (1997) 6891 CA52527 (S.O.-R.) and R01 CA48185 (J.P.-Y.T.) and National Research Service Award F32 CA67480 (B.K.M.). 1. Pardoll, D. (1992) Curr. Opin. Immunol. 4, Ostrand-Rosenberg, S., Thakur, A. & Clements, V. (1990) J. Immunol. 144, Ostrand-Rosenberg, S. (1994) Curr. Opin. Immunol. 6, James, R., Edwards, S., Hui, K., Bassett, P. & Grosveld, F. (1991) Immunology 72, Chen, P. & Ananthaswamy, H. (1993) J. Immunol. 151, Wu, T.-C., Guarnieri, F., Staveley-O Carroll, K., Viscidi, R., Levitsky, H., Hedrick, L., Cho, K., August, J. T. & Pardoll, D. (1995) Proc. Natl. Acad. Sci. USA 92, Ostrand-Rosenberg, S., Baskar, S., Patterson, N. & Clements, V. (1996) Tissue Antigens 47, Baskar, S., Glimcher, L., Nabavi, N., Jones, R. T. & Ostrand- Rosenberg, S. (1995) J. Exp. Med. 181, Trinchieri, G. & Perussia, B. (1985) Immunol. Today 6, Steimle, V., Otten, L., Zufferey, M. & Mach, B. (1993) Cell 75, Momburg, F., Koch, N., Moller, P., Moldenhauer, G., Butcher, G. & Hammerling, G. (1986) J. Immunol. 136, Chang, C. H. & Flavell, R. A. (1995) J. Exp. Med. 181, Kern, I., Steimle, V., Siegrist, C. & Mach, B. (1995) Int. Immunol. 7, Baskar, S., Ostrand-Rosenberg, S., Nabavi, N., Nadler, L. M., Freeman, G. J. & Glimcher, L. H. (1993) Proc. Natl. Acad. Sci. USA 90, Clements, V. K., Armstrong, T., Baskar, S. & Ostrand-Rosenberg, S. (1992) J. Immunol. 149, Hartley, J., Crosbic, J., Brink, R., Kantor, A., Basten, A. & Goodnow, C. (1991) Nature (London) 353, Munro, S. & Pelham, H. (1987) Cell 48, Karasuyama, H. & Melchers, F. (1988) Eur. J. Immunol. 18, Olsen, J. C. & Sechelski, J. (1995) Hum. Gene Ther. 6, Johnson, N., Cavland, A., Allen, P. & Glimcher, L. (1989) J. Immunol. 142, Glimcher, L., Hamano, T., Asofsky, R., Sachs, D., Pierres, M., Samelson, L., Sharrow, S. & Paul, W. (1983) J. Immunol. 130, Rosloniec, E., Gay, D. & Freed, J. (1989) J. Immunol. 142, Smith-Gill, S., Lavoie, T. & Mainhart, C. (1984) J. Immunol. 133, Oi, V., Jones, P., Goding, J., Herzenberg, L. & Herzenberg, L. (1978) Curr. Top. Microbiol. Immunol. 81, Karlsson, L., Peleraux, A., Lindstedt, R., Liljedahl, M. & Peterson, P. A. (1994) Science 266, Steimle, V., Siegrist, C. A., Mottet, A., Lisowska-Grospierre, B. & Mach, B. (1994) Science 265, Chin, K.-C., Mao, C., Skinner, C., Riley, J. L., Wright, K. L., Moreno, C. S., Stark, G. R., Boss, J. M. & Ting, J. P. Y. (1994) Immunity 1, Chang, C. H., Fontes, J. D., Peterlin, M. & Flavell, R. A. (1994) J. Exp. Med. 180, Mach, B., Steimle, V., Martinez-Soria, E. & Reith, W. (1996) Annu. Rev. Immunol. 14, Ostrand-Rosenberg, S., Roby, C. A. & Clements, V. K. (1991) J. Immunol. 147, Berendt, M., North, R. & Kirstein, D. (1978) J. Exp. Med. 148, Nadimi, F., Moreno, J., Momburg, F., Heuser, A., Fuchs, S., Adorini, L. & Hammerling, G. (1991) Eur. J. Immunol. 21, Brooks, A., Campbell, P., Reynolds, P., Gautam, A. & McCluskey, J. (1994) J. Immunol. 153, Germain, R. (1993) Annu. Rev. Immunol. 11, Lopez-Nevot, M., Garcia, E., Romero, C., Oliva, M., Serrano, S. & Garrido, F. (1988) Exp. Clin. Immunogenet. 5, Cabrera, T., Ruiz-Cabello, F. & Garrido, F. (1995) Scan. J. Immunol. 41, Ostrand-Rosenberg, S., Cole, G. A., Nishimura, M. I. & Clements, V. K. (1990) Cell. Immunol. 128, Nuchtern, J., Biddison, W. & Klausner, R. (1990) Nature (London) 343, Miller, J. & Germain, R. (1986) J. Exp. Med. 164, Sekaly, R. P., Tonnelle, C., Strubin, M., Mach, B. & Long, E. O. (1986) J. Exp. Med. 164, Jaraquemada, D., Marti, M. & Long, E. (1990) J. Exp. Med. 172, Jacobson, S., Sekaly, R., Jacobson, C., McFarland, H. & Long, E. (1989) J. Virol. 63, Xu, X. & Pierce, S. (1995) J. Immunol. 155, Busch, R., Cloutier, I., Sekaly, R. & Hammerling, G. (1996) EMBO J. 15, Rudensky, A., Preston-Hurlburt, P., Hong, S., Barlow, A. & Janeway, C. (1991) Nature (London) 353, Vivelle, S., Neefjes, J., Lotteau, V., Dierich, A., Lemeur, M., Ploegh, H., Benoist, C. & Mathis, D. (1993) Cell 72, Elliott, E., Drake, J., Amigorena, S., Elsemore, J., Webster, P., Mellman, I. & Flavell, R. (1994) J. Exp. Med. 179, Bikoff, E., Huang, L.-Y., Episkopou, V., Meerwijk, J., Germain, R. & Robertson, E. (1993) J. Exp. Med. 177, Bikoff, E., Germain, R. & Robertson, E. (1995) Immunity 2, Chen, P., Ullrich, S. & Ananthaswamy, H. (1994) J. Leukocyte Biol. 56, Mulligan, R. (1993) Science 260, Nabel, G., Gordon, D., Bishop, D., Nickoloff, B., Yang, Z., Aruga, A., Cameron, M., Nabel, E. & Chang, A. (1996) Proc. Natl. Acad. Sci. USA 93, Robbins, P. & Kawakami, Y. (1996) Curr. Opin. Immunol. 8, Pardoll, D. (1996) Curr. Opin. Immunol. 8, Boon, T., Cerrotini, J., Van Pel, A. & van der Bruggen, P. (1994) Annu. Rev. Immunol. 12, Tahara, H., Zeh, H., Storkus, W., Pappo, I., Watkins, C., Gubler, U., Wolf, S., Robbins, P. & Lotze, M. (1994) Canc. Res. 54, Kundig, T., Bachmann, M., DiPaolo, C., Simard, J., Battegay, M., Lother, H., Gessner, A., Kuhlcke, K., Ohashi, P., Hengartner, H. & Zinkernagel, R. (1995) Science 268, Chin, K.-C., Li, G. & Ting, J. P.-Y. (1997) Proc. Natl. Acad. Sci. USA 94,
MHC Class II Presentation of Endogenous Tumor Antigen by Cellular Vaccines Depends on the Endocytic Pathway but not H2-M
Traffic 2000 1: 152 160 Munksgaard International Publishers MHC Class II Presentation of Endogenous Tumor Antigen by Cellular Vaccines Depends on the Endocytic Pathway but not H2-M Ling Qi and Suzanne
Research Article. Abstract. Introduction
Tumor Cells Transduced with the MHC Class II Transactivator and CD80 Activate Tumor-Specific CD4 + T Cells Whether or Not They Are Silenced for Invariant Chain James A. Thompson, 1 Samudra K. Dissanayake,
Supplemental Figure 1. Cell-bound Cetuximab reduces EGFR staining intensity. Blood
Antibody-mediated depletion of CD19-CAR T cells Supplemental 1 Supplemental Materials Supplemental Figure 1. Supplemental Figure 1. Cell-bound Cetuximab reduces EGFR staining intensity. Blood cells were
TITLE: Novel MHC Class II Breast Cancer Vaccine Using RNA Interference (RNAi) to Down Regulate Invariant Chain (Ii)
AD AWARD NUMBER: DAMD17-03-1-0337 TITLE: Novel MHC Class II Breast Cancer Vaccine Using RNA Interference (RNAi) to Down Regulate Invariant Chain (Ii) PRINCIPAL INVESTIGATOR: James A. Thompson CONTRACTING
Oncolytic Immunotherapy: A Local and Systemic Antitumor Approach
Oncolytic Immunotherapy: A Local and Systemic Antitumor Approach Oncolytic immunotherapy Oncolytic immunotherapy the use of a genetically modified virus to attack tumors and induce a systemic immune response
Significance of the MHC
CHAPTER 8 Major Histocompatibility Complex (MHC) What is is MHC? HLA H-2 Minor histocompatibility antigens Peter Gorer & George Sneell (1940) Significance of the MHC role in immune response role in organ
CT411, and RW17C were obtained from a single donor's peripheral
Proc. Natl. Acad. Sci. USA Vol. 81, pp. 1509-1513, March 1984 Immunology Triggering of the T3-Ti antigen-receptor complex results in clonal T-cell proliferation through an interleukin 2-dependent autocrine
Significance of the MHC
CHAPTER 8 Major Histocompatibility Complex (MHC) What is MHC? HLA H-2 Minor histocompatibility antigens Peter Gorer & George Sneell (1940) - MHC molecules were initially discovered during studies aimed
Tumor Immunology. Wirsma Arif Harahap Surgical Oncology Consultant
Tumor Immunology Wirsma Arif Harahap Surgical Oncology Consultant 1) Immune responses that develop to cancer cells 2) Escape of cancer cells 3) Therapies: clinical and experimental Cancer cells can be
Blocking antibodies and peptides. Rat anti-mouse PD-1 (29F.1A12, rat IgG2a, k), PD-
Supplementary Methods Blocking antibodies and peptides. Rat anti-mouse PD-1 (29F.1A12, rat IgG2a, k), PD- L1 (10F.9G2, rat IgG2b, k), and PD-L2 (3.2, mouse IgG1) have been described (24). Anti-CTLA-4 (clone
A second type of TCR TCR: An αβ heterodimer
How s recognize antigen: The T Cell Receptor (TCR) Identifying the TCR: Why was it so hard to do By the early 1980s, much about function was known, but the receptor genes had not been identified Recall
Bead Based Assays for Cytokine Detection
Bead Based Assays for Cytokine Detection September 27, 2014 6 th EFIS-EJI South East European Immunology School SEEIS 2014 Timisoara, Romania The Cells of the Immune System The Immune Reaction (Th2) (Th1)
Scott Abrams, Ph.D. Professor of Oncology, x4375 Kuby Immunology SEVENTH EDITION
Scott Abrams, Ph.D. Professor of Oncology, x4375 scott.abrams@roswellpark.org Kuby Immunology SEVENTH EDITION CHAPTER 11 T-Cell Activation, Differentiation, and Memory Copyright 2013 by W. H. Freeman and
Scott Abrams, Ph.D. Professor of Oncology, x4375 Kuby Immunology SEVENTH EDITION
Scott Abrams, Ph.D. Professor of Oncology, x4375 scott.abrams@roswellpark.org Kuby Immunology SEVENTH EDITION CHAPTER 11 T-Cell Activation, Differentiation, and Memory Copyright 2013 by W. H. Freeman and
Gregory M. Barton 1,2 and Alexander Y. Rudensky 1,3. Institute, University of Washington School of Medicine, Seattle, WA 98195, USA
International Immunology, Vol. 10, No. 8, pp. 1159 1165 1998 Oxford University Press An altered invariant chain protein with an antigenic peptide in place of CLIP forms SDS-stable complexes with class
Anti-Tumor Efficacy of Gene Vaccine Expressing PSMA
6 Clin Oncol Cancer Res () 7: 6-5 DOI.7/s85--5-7 Anti-Tumor Efficacy of Gene Vaccine Expressing PSMA Xiao-ling YANG Jing LV Yue-hong ZHANG Bo NIU, Department of Laboratory Medicine, Shanxi Bo ai Hospital,
MHC class I MHC class II Structure of MHC antigens:
MHC class I MHC class II Structure of MHC antigens: MHC class I antigens consist of a transmembrane heavy chain (α chain) that is non-covalently associated with β2- microglobulin. Membrane proximal domain
Antigen presenting cells
Antigen recognition by T and B cells - T and B cells exhibit fundamental differences in antigen recognition - B cells recognize antigen free in solution (native antigen). - T cells recognize antigen after
Chapter 22: The Lymphatic System and Immunity
Bio40C schedule Lecture Immune system Lab Quiz 2 this week; bring a scantron! Study guide on my website (see lab assignments) Extra credit Critical thinking questions at end of chapters 5 pts/chapter Due
Chapter 6. Antigen Presentation to T lymphocytes
Chapter 6 Antigen Presentation to T lymphocytes Generation of T-cell Receptor Ligands T cells only recognize Ags displayed on cell surfaces These Ags may be derived from pathogens that replicate within
Immunology Lecture 4. Clinical Relevance of the Immune System
Immunology Lecture 4 The Well Patient: How innate and adaptive immune responses maintain health - 13, pg 169-181, 191-195. Immune Deficiency - 15 Autoimmunity - 16 Transplantation - 17, pg 260-270 Tumor
the HLA complex Hanna Mustaniemi,
the HLA complex Hanna Mustaniemi, 28.11.2007 The Major Histocompatibility Complex Major histocompatibility complex (MHC) is a gene region found in nearly all vertebrates encodes proteins with important
Antigen Presentation to T lymphocytes
Antigen Presentation to T lymphocytes Immunology 441 Lectures 6 & 7 Chapter 6 October 10 & 12, 2016 Jessica Hamerman jhamerman@benaroyaresearch.org Office hours by arrangement Antibodies and T cell receptors
LAMPvax DNA Vaccines as Immunotherapy for Cancer - Three Case Studies
LAMPvax DNA Vaccines as Immunotherapy for Cancer - Three Case Studies Cancer immunotherapy has emerged as a clinically validated tool for fighting certain kinds of cancers. These therapeutic cancer vaccines
High efficiency of endogenous antigen presentation by MHC class II molecules
International Immunology. Vol. 4, No. 10, pp. 1113-1121 1992 Oxford University Press High efficiency of endogenous antigen presentation by MHC class II molecules Veronique Calin-Laurens, Frederique Forquet,
Practical Solution: presentation to cytotoxic T cells. How dendritic cells present antigen. How dendritic cells present antigen
Christian Kurts Institutes of Molecular Medicine and Experimental Immunology University of Bonn, Germany - presentation and (CTL) activation - I presentation and CD4 + T cell (Th cell) activation Different
The Major Histocompatibility Complex (MHC)
The Major Histocompatibility Complex (MHC) An introduction to adaptive immune system before we discuss MHC B cells The main cells of adaptive immune system are: -B cells -T cells B cells: Recognize antigens
VIRAL TITER COUNTS. The best methods of measuring infectious lentiviral titer
VIRAL TITER COUNTS The best methods of measuring infectious lentiviral titer FLUORESCENCE CYCLES qpcr of Viral RNA SUMMARY Viral vectors are now routinely used for gene transduction in a wide variety of
Tumor responses (patients responding/ patients treated)
Table 1. ACT clinical trial tumor responses and toxicities. a Target antigen Cancer(s) Receptor type Tumor responses (patients responding/ patients treated) Immune-mediated toxicities (patients experiencing
Integrin v 3 targeted therapy for Kaposi s sarcoma with an in vitro evolved antibody 1
Integrin v 3 targeted therapy for Kaposi s sarcoma with an in vitro evolved antibody 1 CHRISTOPH RADER, 2 MIKHAIL POPKOV, JOHN A. NEVES, AND CARLOS F. BARBAS III 2 Department of Molecular Biology and The
Bioassays for Quality Control of Cell & Gene Therapy Products
Bioassays for Quality Control of Cell & Gene Therapy Products Erik Rutjens, Cell & Gene Therapy, Novartis Pharma AG CASSS Bioassays, Silver Spring, March2015 CTL019 Introduction CARTs = Chimeric Antigen
Medical Virology Immunology. Dr. Sameer Naji, MB, BCh, PhD (UK) Head of Basic Medical Sciences Dept. Faculty of Medicine The Hashemite University
Medical Virology Immunology Dr. Sameer Naji, MB, BCh, PhD (UK) Head of Basic Medical Sciences Dept. Faculty of Medicine The Hashemite University Human blood cells Phases of immune responses Microbe Naïve
Significance of the MHC
CHAPTER 7 Major Histocompatibility Complex (MHC) What is is MHC? HLA H-2 Minor histocompatibility antigens Peter Gorer & George Sneell (1940) Significance of the MHC role in immune response role in organ
ACTR (Antibody Coupled T-cell Receptor): A universal approach to T-cell therapy
ACTR (Antibody Coupled T-cell Receptor): A universal approach to T-cell therapy European Medicines Agency Workshop on Scientific and Regulatory Challenges of Genetically Modified Cell-based Cancer Immunotherapy
Immunobiology, BIOL 537 Spring 2013
Immunobiology, BIOL 537 Spring 2013 Instructor: Dr. Elliott Blumenthal Office: Science Building, # 390 Class Meets: 6:00-7:15 PM TR Phone: 481-6004 E-mail: Blumenth@ipfw.edu SB 168 481-6305 (Biology Office)
CELLULAR AND MOLECULAR REQUIREMENTS FOR REJECTION OF B16 MELANOMA IN THE SETTING OF REGULATORY T CELL DEPLETION AND HOMEOSTATIC PROLIFERATION
CELLULAR AND MOLECULAR REQUIREMENTS FOR REJECTION OF B16 MELANOMA IN THE SETTING OF REGULATORY T CELL DEPLETION AND HOMEOSTATIC PROLIFERATION Justin Kline 1, Long Zhang 1, and Thomas F. Gajewski 1,2 Departments
Utilizing AlphaLISA Technology to Screen for Inhibitors of the CTLA-4 Immune Checkpoint
APPLICATION NOTE AlphaLISA Technology Authors: Matthew Marunde Stephen Hurt PerkinElmer, Inc. Hopkinton, MA Utilizing AlphaLISA Technology to Screen for Inhibitors of the CTLA-4 Immune Checkpoint Introduction
ADCC Assay Protocol Vikram Srivastava 1, Zheng Yang 1, Ivan Fan Ngai Hung 2, Jianqing Xu 3, Bojian Zheng 3 and Mei- Yun Zhang 3*
ADCC Assay Protocol Vikram Srivastava 1, Zheng Yang 1, Ivan Fan Ngai Hung 2, Jianqing Xu 3, Bojian Zheng 3 and Mei- Yun Zhang 3* 1 Department of Microbiology, Li Ka Shing Faculty of Medicine, University
Downloaded by on April 28, 2018 https://pubs.acs.org Publication Date: April 24, 1984 doi: /bk
1 Virus-Receptor Interactions BERNARD N. FIELDS Department of Microbiology and Molecular Genetics, Harvard Medical School, and Department of Medicine (Infectious Disease), Brigham and Women's Hospital,
The phenotype of H-2M-deficient mice is dependent on the MHC class II molecules expressed
Eur. J. Immunol. 1998. 28: 2605 2618 Allelic/isotypic differences in H-2M dependency 2605 The phenotype of H-2M-deficient mice is dependent on the MHC class II molecules expressed Paula R. Wolf 1, Sylvie
Automated manufacture of T-cell immunotherapies using gamma retroviral transduction. Lee Markwick, PhD. AMC, Manchester March 2018
Automated manufacture of T-cell immunotherapies using gamma retroviral transduction Lee Markwick, PhD AMC, Manchester March 2018 Automated generation of CAR T cells Starting material d0 T cell enrichment
Cancer Vaccines and Combination Immunotherapy
Cancer Vaccines and Combination Immunotherapy Bernard A. Fox, PhD Harder Family Chair for Cancer Research Member and Chief, Laboratory of Molecular and Tumor Immunology Earle A. Chiles Research Institute
Bihong Zhao, M.D, Ph.D Department of Pathology
Bihong Zhao, M.D, Ph.D Department of Pathology 04-28-2009 Is tumor self or non-self? How are tumor antigens generated? What are they? How does immune system respond? Introduction Tumor Antigens/Categories
Profiling HLA motifs by large scale peptide sequencing Agilent Innovators Tour David K. Crockett ARUP Laboratories February 10, 2009
Profiling HLA motifs by large scale peptide sequencing 2009 Agilent Innovators Tour David K. Crockett ARUP Laboratories February 10, 2009 HLA Background The human leukocyte antigen system (HLA) is the
Engineered Immune Cells for Cancer Therapy : Current Status and Prospects
When Engineering Meets Immunology Engineered Immune Cells for Cancer Therapy : Current Status and Prospects Yong Taik Lim, Ph.D. Nanomedical Systems Laboratory (http://www.nanomedicalsystems.org) SKKU
HLA and antigen presentation. Department of Immunology Charles University, 2nd Medical School University Hospital Motol
HLA and antigen presentation Department of Immunology Charles University, 2nd Medical School University Hospital Motol MHC in adaptive immunity Characteristics Specificity Innate For structures shared
Using the immune response to attack tumors. Antonio-Mario Kobaš June 28, 2017
Using the immune response to attack tumors Antonio-Mario Kobaš June 28, 2017 Contents Introduction Main part Transplantation of tumors in mice Tumors and the immune system Treatment of cancer Summary 2
Superior Fluorescent Labeling Dyes Spanning the Full Visible Spectrum...1. Trademarks: HiLyte Fluor (AnaSpec, Inc.)
Table of Contents Fluor TM Labeling Dyes Superior Fluorescent Labeling Dyes Spanning the Full Visible Spectrum....1 Fluor TM 405 Dye, an Excellent Alternative to Alexa Fluor 405 & DyLight 405....2 Fluor
Supplementary Figures
Supplementary Figures Supplementary Figure 1. NKT ligand-loaded tumour antigen-presenting B cell- and monocyte-based vaccine induces NKT, NK and CD8 T cell responses. (A) The cytokine profiles of liver
Antigen Presentation to Lymphocytes
Antigen Presentation to Lymphocytes Jiyang O Wang, Chiba Cancer Center Research Institute, Chiba, Japan Takeshi Watanabe, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Japan Antigen presentation
The Immune System. These are classified as the Innate and Adaptive Immune Responses. Innate Immunity
The Immune System Biological mechanisms that defend an organism must be 1. triggered by a stimulus upon injury or pathogen attack 2. able to counteract the injury or invasion 3. able to recognise foreign
Phase of immune response
Antigen and antigen recognition by lymphocytes Antigen presentation to T lymphocytes Sanipa Suradhat Department of Veterinary Microbiology Faculty of Veterinary Science Phase of immune response 1 Phase
Physiology Unit 3. ADAPTIVE IMMUNITY The Specific Immune Response
Physiology Unit 3 ADAPTIVE IMMUNITY The Specific Immune Response In Physiology Today The Adaptive Arm of the Immune System Specific Immune Response Internal defense against a specific pathogen Acquired
TSH Receptor Monoclonal Antibody (49) Catalog Number MA3-218 Product data sheet
Website: thermofisher.com Customer Service (US): 1 800 955 6288 ext. 1 Technical Support (US): 1 800 955 6288 ext. 441 TSH Receptor Monoclonal Antibody (49) Catalog Number MA3-218 Product data sheet Details
Tumors arise from accumulated genetic mutations. Tumor Immunology (Cancer)
Tumor Immunology (Cancer) Tumors arise from accumulated genetic mutations Robert Beatty MCB150 Mutations Usually have >6 mutations in both activation/growth factors and tumor suppressor genes. Types of
Cytotoxicity assays. Rory D. de Vries, PhD 1. Viroscience lab, Erasmus MC, Rotterdam, the Netherlands
Cytotoxicity assays Rory D. de Vries, PhD 1 1 Viroscience lab, Erasmus MC, Rotterdam, the Netherlands Anti-influenza immunity Humoral / CD4+ / CD8+ / NK? Function of CTL Elimination of virus-infected cells?
Key words: Collagen synthesis - N-Terminal peptide of type III procollagen - Tumor marker - Liver cancer - Liver cirrhosis
[Gann, 75, 130-135; February, 1984] HIGH CONCENTRATIONS OF N-TERMINAL PEPTIDE OF TYPE III PROCOLLAGEN IN THE SERA OF PATIENTS WITH VARIOUS CANCERS, WITH SPECIAL REFERENCE TO LIVER CANCER Terumasa HATAHARA,
Fast and Easy Isolation of T Cells
Fast and Easy Isolation of T Cells Isolate T Cells In As Little As 25 Minutes Isolate whole T cell populations as well as various T cell subsets with high purity and recovery using the fast and easy T
Tumor Immunity and Immunotherapy. Andrew Lichtman M.D., Ph.D. Brigham and Women s Hospital Harvard Medical School
Tumor Immunity and Immunotherapy Andrew Lichtman M.D., Ph.D. Brigham and Women s Hospital Harvard Medical School Lecture Outline Evidence for tumor immunity Types of tumor antigens Generation of anti-tumor
Madhav V. Dhodapkar, Joseph Krasovsky, Ralph M. Steinman, and Nina Bhardwaj
Mature dendritic cells boost functionally superior CD8 + T-cell in humans without foreign helper epitopes Rapid PUBLICATION Madhav V. Dhodapkar, Joseph Krasovsky, Ralph M. Steinman, and Nina Bhardwaj Laboratory
Posters and Presentations
Posters and Presentations June 2017: American Society of Clinical Oncology (ASCO) Annual - Preliminary Correlative Analysis of PD-L1 expression from the SUNRISE Study. View April 2017: American Association
T-cell activation T cells migrate to secondary lymphoid tissues where they interact with antigen, antigen-presenting cells, and other lymphocytes:
Interactions between innate immunity & adaptive immunity What happens to T cells after they leave the thymus? Naïve T cells exit the thymus and enter the bloodstream. If they remain in the bloodstream,
Introduction. W Song 1, Y Tong 1, H Carpenter 1, H-L Kong 1 and RG Crystal 1,2 1
(2000) 7, 2080 2086 2000 Macmillan Publishers Ltd All rights reserved 0969-7128/00 $15.00 www.nature.com/gt ACQUIRED DISEASES RESEARCH ARTICLE Persistent, antigen-specific, therapeutic antitumor immunity
L-selectin Is Essential for Delivery of Activated CD8 + T Cells to Virus-Infected Organs for Protective Immunity
Cell Reports Supplemental Information L-selectin Is Essential for Delivery of Activated CD8 + T Cells to Virus-Infected Organs for Protective Immunity Rebar N. Mohammed, H. Angharad Watson, Miriam Vigar,
Critical Role for Alpha/Beta and Gamma Interferons in Persistence of Lymphocytic Choriomeningitis Virus by Clonal Exhaustion of Cytotoxic T Cells
JOURNAL OF VIROLOGY, Sept. 2001, p. 8407 8423 Vol. 75, No. 18 0022-538X/01/$04.00 0 DOI: 10.1128/JVI.75.18.8407 8423.2001 Copyright 2001, American Society for Microbiology. All Rights Reserved. Critical
Supplementary Table; Supplementary Figures and legends S1-S21; Supplementary Materials and Methods
Silva et al. PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability Supplementary Table; Supplementary Figures and legends S1-S21; Supplementary
Combining ADCs with Immuno-Oncology Agents
Combining ADCs with Immuno-Oncology Agents Chad May, PhD Senior Director Targeted Immunotherapy Oncology Research Unit, Pfizer 7 th Annual World ADC October 10, 2016 Cancer-Immunity Cycle Innate Immunity
Rabies virus-like particles expressed in HEK293 cells
Engineering Conferences International ECI Digital Archives Vaccine Technology IV Proceedings Spring 5-21-2012 Rabies virus-like particles expressed in HEK293 cells Diego Fontana Cell Culture Laboratory
B F. Location of MHC class I pockets termed B and F that bind P2 and P9 amino acid side chains of the peptide
Different MHC alleles confer different functional properties on the adaptive immune system by specifying molecules that have different peptide binding abilities Location of MHC class I pockets termed B
Basic Immunology. Lecture 5 th and 6 th Recognition by MHC. Antigen presentation and MHC restriction
Basic Immunology Lecture 5 th and 6 th Recognition by MHC. Antigen presentation and MHC restriction Molecular structure of MHC, subclasses, genetics, functions. Antigen presentation and MHC restriction.
A revised model for invariant chain-mediated assembly of MHC class II peptide receptors
Opinion TRENDS in Biochemical Sciences Vol.32 No.12 A revised model for invariant chain-mediated assembly of MHC class II peptide receptors Norbert Koch 1, Alexander D. McLellan 2 and Jürgen Neumann 1
Structure and Function of Antigen Recognition Molecules
MICR2209 Structure and Function of Antigen Recognition Molecules Dr Allison Imrie allison.imrie@uwa.edu.au 1 Synopsis: In this lecture we will examine the major receptors used by cells of the innate and
NF-κB p65 (Phospho-Thr254)
Assay Biotechnology Company www.assaybiotech.com Tel: 1-877-883-7988 Fax: 1-877-610-9758 NF-κB p65 (Phospho-Thr254) Colorimetric Cell-Based ELISA Kit Catalog #: OKAG02015 Please read the provided manual
Unit 5 The Human Immune Response to Infection
Unit 5 The Human Immune Response to Infection Unit 5-page 1 FOM Chapter 21 Resistance and the Immune System: Innate Immunity Preview: In Chapter 21, we will learn about the branch of the immune system
Topics in Parasitology BLY Vertebrate Immune System
Topics in Parasitology BLY 533-2008 Vertebrate Immune System V. Vertebrate Immune System A. Non-specific defenses against pathogens 1. Skin - physical barrier a. Tough armor protein KERATIN b. Surface
Technical Resources. BD Immunocytometry Systems. FastImmune Intracellular Cytokine Staining Procedures
FastImmune Intracellular Cytokine Staining Procedures BD has developed protocols for the detection of intracellular cytokines in activated lymphocytes and in activated monocytes. The procedures have been
Ex-Vivo heat shock protein 70-peptide-activated, autologous natural killer cells adoptive therapy: from the bench to the clinic
Ex-Vivo heat shock protein 70-peptide-activated, autologous natural killer cells adoptive therapy: from the bench to the clinic isbtc 10-13 November 2005 Valeria Milani, MD, PhD Munich Agenda 1. NK ligands
LECTURE: 23 T-AND B-LYMPHOCYTES COOPERATIONS LEARNING OBJECTIVES: The student should be able to:
LECTURE: 23 Title T-AND B-LYMPHOCYTES COOPERATIONS LEARNING OBJECTIVES: The student should be able to: Enumerate the major types of T-helper cells surface molecules, and that expressed on the B-lymphocytes
SEVENTH EDITION CHAPTER
Judy Owen Jenni Punt Sharon Stranford Kuby Immunology SEVENTH EDITION CHAPTER 16 Tolerance, Autoimmunity, and Transplantation Copyright 2013 by W. H. Freeman and Company Immune tolerance: history * Some
Sleeping Beauty: Current applications and future strategies. CAR-TCR Summit 2017 Partow Kebriaei, MD
Sleeping Beauty: Current applications and future strategies CAR-TCR Summit 2017 Partow Kebriaei, MD Outline Chimeric antigen receptor (CAR) technology Viral versus nonviral vectors Results of current clinical
Ready-to-use Lentiviral Particles for intracelular labeling
Ready-to-use Lentiviral Particles for intracelular labeling (LocLight TM Living cell imaging lentivirus for sub-cellular localization) LocLight TM cell organelle labeling lentivirus are provided as 200ul/per
CHAPTER 18: Immune System
CHAPTER 18: Immune System 1. What are four characteristics of the specific immune system? a. b. c. d. 2. List the two main types of defense mechanisms and briefly describe features of each. 3. Give examples
Blocking the expression of the hepatitis B virus S gene in hepatocellular carcinoma cell lines with an anti-gene locked nucleic acid in vitro
Blocking the expression of the hepatitis B virus S gene in hepatocellular carcinoma cell lines with an anti-gene locked nucleic acid in vitro Y.-B. Deng, H.-J. Qin, Y.-H. Luo, Z.-R. Liang and J.-J. Zou
Cancer Immunotherapy: Active Immunization Approaches
Cancer Immunotherapy: Active Immunization Approaches Willem W. Overwijk, PhD Department of Melanoma Medical Oncology MD Anderson Cancer Center Houston, TX, USA Disclosures No relevant financial relationships
Examples of questions for Cellular Immunology/Cellular Biology and Immunology
Examples of questions for Cellular Immunology/Cellular Biology and Immunology Each student gets a set of 6 questions, so that each set contains different types of questions and that the set of questions
Regulation of anti-tumor immunity through migration of immune cell subsets within the tumor microenvironment Thomas F. Gajewski, M.D., Ph.D.
Regulation of anti-tumor immunity through migration of immune cell subsets within the tumor microenvironment Thomas F. Gajewski, M.D., Ph.D. Professor, Departments of Pathology and Medicine Program Leader,
Phagocytosis of FITC labelled opsonized and non-opsonized E. coli bacteria by monocytes and granulocytes in a whole blood assay
Phagocytosis of FITC labelled opsonized and non-opsonized E. coli bacteria by monocytes and granulocytes in a whole blood assay APPLICATION NOTE Author: Andreas Spittler, MD, Associate Professor for Pathophysiology
All animals have innate immunity, a defense active immediately upon infection Vertebrates also have adaptive immunity
1 2 3 4 5 6 7 8 9 The Immune System All animals have innate immunity, a defense active immediately upon infection Vertebrates also have adaptive immunity Figure 43.2 In innate immunity, recognition and
Cancer Immunotherapy. What is it? Immunotherapy Can Work! 4/15/09. Can the immune system be harnessed to fight cancer? T CD4 T CD28.
Cancer Immunotherapy CANCER BIOLOGY April 15, 2009 Can the immune system be harnessed to fight cancer? Can the immune system see cancer? What is the best way to turn on the immune system to fight cancer?
Focused Ultrasound and Cancer Immunotherapy
Focused Ultrasound and Cancer Immunotherapy Overview A number of therapeutic modalities including radiation, radiofrequency and laser-induced heating, cryoablation, and focused ultrasound have been shown
Intracellular localization and association of MHC class I with porcine invariant chain
Intracellular localization and association of MHC class I with porcine invariant chain F.Z. Xu 1, S.G. Wu 2 and W.Y. Yu 1 1 Anhui Agricultural University, Hefei, China 2 Anhui AnFengTang Animal Medicine
Tumor Immunology. Tumor (latin) = swelling
Tumor Immunology Tumor (latin) = swelling benign tumor malignant tumor Tumor immunology : the study of the types of antigens that are expressed by tumors how the immune system recognizes and responds to
MELANOMA CANCER TEST
MELANOMA CANCER TEST Efficacy Evaluation of Antitumor Activity of Alka Vita - Alkahydroxy in the LOX-GFP Human Melanoma Model Final Report by: Anti-Cancer Lab San Diego California March 4, 2005 Efficacy
Cancer immunotherapy with oncolytic viruses: more than just lysis
Cancer immunotherapy with oncolytic viruses: more than just lysis Dmitriy Zamarin MD PhD Assistant Attending, Immune Therapeutics Center Memorial Sloan-Kettering Cancer Center New York, NY BCAN Think Tank
Gladstone Institutes, University of California (UCSF), San Francisco, USA
Fluorescence-linked Antigen Quantification (FLAQ) Assay for Fast Quantification of HIV-1 p24 Gag Marianne Gesner, Mekhala Maiti, Robert Grant and Marielle Cavrois * Gladstone Institutes, University of
Rabbit Polyclonal antibody to NFkB p65 (v-rel reticuloendotheliosis viral oncogene homolog A (avian))
Datasheet GeneTex, Inc : Toll Free 1-877-GeneTex (1-877-436-3839) Fax:1-949-309-2888 info@genetex.com GeneTex International Corporation : Tel:886-3-6208988 Fax:886-3-6208989 infoasia@genetex.com Date :
7/14/2014. Multiple immune effector mechanisms contribute to protection influenza. What is a correlate of protection?
What is a correlate of protection? Immunological Assessment of Influenza Vaccines and Correlates of Protection Jacqueline Katz Influenza Division Centers for Disease Control and Prevention Defined immune
11/25/2017. THE IMMUNE SYSTEM Chapter 43 IMMUNITY INNATE IMMUNITY EXAMPLE IN INSECTS BARRIER DEFENSES INNATE IMMUNITY OF VERTEBRATES
THE IMMUNE SYSTEM Chapter 43 IMMUNITY INNATE IMMUNITY EXAMPLE IN INSECTS Exoskeleton made of chitin forms the first barrier to pathogens Digestive system is protected by a chitin-based barrier and lysozyme,
BBS 2711 Virology. Virus Vaccines
BBS 2711 Virology Virus Vaccines Dr Paul Young, Department of Microbiology & Parasitology. p.young@mailbox.uq.edu.au Virus Vaccines First vaccine developed by Jenner in late 1700's against smallpox virus